Both DPP-4 and SGLT2 inhibitors have been selected as the first choice for type 2 diabetes in Japanese clinical practice, and they are appropriate active comparators in the Japanese context. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.